

Saniona At-A-Glance

Fast Facts

Saniona is a clinical-stage biopharmaceutical company focused on **discovering, developing and delivering innovative treatments for people with rare diseases**. Our foundation is built on more than 20 years of pioneering ion channel research. We are advancing multiple potential new medicines through clinical and preclinical studies, and we've leveraged our ion channel drug discovery engine to generate a library of more than 20,000 proprietary molecules.

- Publicly-traded (OMX: SANION) on the Nasdaq Stockholm Small Cap
- Facilities in Copenhagen, Denmark (research team) and Boston, Mass., U.S. (corporate office)
- 38 full-time employees as of Dec. 31, 2020
- Strong institutional support from RA Capital, Pontifax Venture Capital, New Leaf Venture Partners and other U.S. and international investors

Ion Channel Innovation



Saniona is a leader in the discovery of highly specific ion channel modulators. Ion channel modulation is a validated approach to treating disease and has been used in medicines for diabetes, hypertension, epilepsy and more. Yet targeting ion channels is so difficult that an estimated 80% of them have yet to be accessed for drug development.

Our research team has leveraged our expertise and proprietary methods to design a robust ion channel drug discovery engine and generate a library of more than **20,000 proprietary molecules** targeting various subtypes of ion channels. We are currently advancing multiple candidates that we believe can make a meaningful difference in the lives of patients.

Proprietary Pipeline

Our most advanced therapies include Tesomet, SAN711 and SAN903.

Product	Indication	Preclinical	Phase 1	Phase 2a	Phase 2b	Phase 3
Tesomet (tesofensine + metoprolol)	Hypothalamic Obesity	[Progress bar]				
	Prader-Willi syndrome	[Progress bar]				
SAN711 (GABA α 3 PAM)	Rare neuropathic disorders	[Progress bar]				
SAN903 (IK channel blocker)	Rare inflammatory disorders	[Progress bar]				

TESOMET

Tesomet is an investigational fixed-dose combination of tesofensine (a triple monoamine reuptake inhibitor) and metoprolol (a beta-1 selective blocker). Saniona is advancing Tesomet for hypothalamic obesity and Prader-Willi syndrome, two severe rare disorders characterized by obesity and loss of appetite control. The programs are currently in clinical development. Saniona holds worldwide rights to Tesomet and is actively evaluating opportunities to advance this treatment globally.

SAN711

SAN711 is a first-in-class positive allosteric modulator of GABAA α 3 receptors in development for rare neuropathic disorders. SAN711 has the potential to provide pain relief and other benefits in the central nervous system with fewer side effects than benzodiazepines (i.e. Valium), which hit all of the GABAA receptors indiscriminately.

SAN903

SAN903 is a potential first-in-class inhibitor of the calcium-activated potassium ion channel, $K_{Ca}3.1$. It is currently in preclinical development for the treatment of rare inflammatory and fibrotic disorders, such as idiopathic pulmonary fibrosis and the anemia disease hereditary xerocytosis (HX).

Patient Advocacy



Our passion for helping patients is in our DNA. That is why one of our key pillars is our Patient Advocacy team, whose goal is to ensure patient and family voices help shape us from the start. We're listening to, learning from and partnering with patients, caregivers and patient advocacy organizations in a way that is aligned with our core values.

Diversity and Inclusion



We firmly believe in an inclusive culture that embraces and celebrates all employees regardless of race, ethnicity, religion, age, gender identity, and disability. Fostering an environment built on diversity and inclusion enhances trust, collaboration, and innovation, which will ultimately allow us to better serve the rare disease community.

Core Values

Put people first: Treat all people with kindness, respect and equity. Support people on their journey and enable a sense of belonging.

Innovation with impact: Push boundaries with courage. Embrace empowerment. And deliver excellence.

Integrity, always: Maintain the highest ethical standards in all that we do as we deliver with urgency for patients in need.